Treatment study for stage II-III triple-negative breast cancer before surgery
Part of Cancer, Skin clinical trials.
This trial tests adding the immunotherapy drugs JS004 and toripalimab to standard chemotherapy before surgery for stage II-III triple-negative breast cancer. It aims to see if combining these immunotherapies with chemo works better than chemo alone or chemo with just toripalimab.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have been newly diagnosed with stage II or III triple-negative breast cancer that has not spread to other parts of the body.
- Your tumor does not have receptors for estrogen, progesterone, or HER2 (triple-negative).
- You have not had any previous treatment for breast cancer, such as chemotherapy, radiation, or surgery.
- You are in good general health, with no serious heart, lung, or other major medical conditions.
- You agree to use effective birth control during the study and for 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding toripalimab (an immunotherapy drug) to chemotherapy before surgery for early-stage triple-negative breast cancer. It aims to see if this combination works better than chemotherapy alone.
This trial tests whether giving chemotherapy plus the immunotherapy drug toripalimab before surgery can improve outcomes for women with early-stage triple-negative breast cancer that tests positive for PD-L1.
This trial tests whether adding sintilimab (an immunotherapy) and bevacizumab (a drug that blocks blood supply to tumors) to standard chemotherapy before surgery can improve outcomes for women with stage II or III triple-negative breast cancer. It may help your immune system fight the cancer more effectively.
This trial tests if combining an immunotherapy drug (toripalimab) with targeted radiation (SBRT) can help people with triple-negative breast cancer that did not shrink after initial chemotherapy. It aims to improve outcomes before surgery.
This trial tests a combination of chemotherapy and immunotherapy given before surgery for early-stage triple-negative breast cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests a combination of an immunotherapy drug (QL1706) plus standard chemotherapy given before surgery to shrink triple-negative breast cancer. The goal is to see if this approach helps remove the tumor more completely.
Hear when a new TNBC - Triple-Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.